{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not estimable","groupId":"OG000","lowerLimit":"351","upperLimit":"NA","value":"791"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Time elapsed between Day 0 and disease progression, as defined by the International Myeloma Working Group (IMWG) disease response criteria. Disease progression is defined as an increase of \\>25% from lowest response value in any one or more of the following:\n\n* Serum M-component and/or (the absolute increase must be \\> 0.5 g/dL)\n* Urine M-component and/or (the absolute increase must be \\> 200 mg/24 h)\n* Only in patients without measurable serum and urine M-protein levels; the difference between involved and uninvolved free light chain levels. The absolute increase must be \\> 10 mg/dL\n* Bone marrow plasma cell percentage; the absolute percentage must be \\> 10%\n* Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas\n* Development of hypercalcaemia (corrected serum calcium \\> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients treated on Dose Level 1 through Dose Level 6. All patients received Melphalan 200 mg/m\\^2 total (140 mg/m\\^2 total for patients with Creatinine Clearance \\<70 ml/min).\n\nDose Level 1; Bendamustine 30 mg/m\\^2 total Dose Level 2; Bendamustine 60 mg/m\\^2 total Dose Level 3; Bendamustine 90 mg/m\\^2 total Dose Level 4; Bendamustine 120 mg/m\\^2 total Dose Level 5; Bendamustine 150 mg/m\\^2 total Dose Level 6; Bendamustine 225 mg/m\\^2 total","id":"OG000","title":"Phase 1"}],"paramType":"MEDIAN","populationDescription":"Phase 1 includes all patients treated on Phase 1 of the study (Dose Levels 1-6). All cohorts were evaluated as one group for assessment of progression-free survival (PFS), as PFS is a secondary endpoint and there was no intent to stratify by cohort for the analysis. The number of patients per cohort is also too small for to evaluate by cohort.","reportingStatus":"POSTED","timeFrame":"From Day 0 to first incidence of disease progression, up to 1,128 days","title":"Progression-Free Survival (Phase 1)","type":"SECONDARY","unitOfMeasure":"Days"}